Rare Diseases Clinical Research Consortia (RDCRC) for the RDCR Network

罕见疾病临床研究联盟 (RDCRC) 的 RDCR 网络

• 批准号: 8766622
• 负责人: MARK L. BATSHAW
• 金额: $ 125万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-30 至 2019-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8766622
• 关键词: Access to Information; Adult; Affect; Ally; Ammonia; Anabolism; Argininosuccinate lyase deficiency; Attenuated; Biochemical; Biological Markers; Canada; Carbamyl Phosphate; Caregivers; Caring; Cessation of life; Child; Citrullinemia; Clinical; Clinical Investigator; Clinical Management; Clinical Research; Clinical Trials; Cognitive; Collaborations; Cystic Fibrosis; Defect; Development; Disease; Distal; Early Diagnosis; Early identification; Enrollment; Enzymes; Europe; Event; Evidence Based Medicine; Family; Foundations; Functional Magnetic Resonance Imaging; Functional disorder; Funding; Future; Glutamine; Goals; Government; Grant; Guidelines; Health Professional; Hyperammonemia; Hyperargininemia; Impairment; Inborn Errors of Metabolism; Incidence; Individual; Industry; Influentials; Information Dissemination; Injury; Innovative Therapy; International; Intervention; Knowledge; Liver Dysfunction; Liver diseases; Longitudinal Studies; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Measurement; Membrane Transport Proteins; Metabolic; Methodology; Methods; Morbidity - disease rate; N acetyl L glutamate; Natural History; Neonatal Screening; Neurocognitive; Neuropsychological Tests; Newborn Infant; Nitric Oxide; Nitrites; Ornithine carbamoyltransferase deficiency; Orphan; Outcome; Participant; Pathogenesis; Patient Recruitments; Patient advocacy; Patients; Performance; Phase; Phase II Clinical Trials; Phenotype; Physicians; Pilot Projects; Protocols documentation; Public Health; Publications; Quality of life; Rare Diseases; Recruitment Activity; Registries; Research; Research Personnel; Research Project Grants; Research Support; Resources; Risk; Role; Sample Size; Scientist; Site; Surveys; Syndrome; Synthase I; Techniques; Testing; Therapeutic Intervention; Training; Treatment Protocols; Treatment outcome; United States National Institutes of Health; Urea; Urease; Work; advocacy organizations; arginase; argininosuccinate synthase; career development; cytokine; data management; improved; inhibitor/antagonist; innovation; member; microbiome; mortality; neuroimaging; neuropsychological; next generation; novel; novel strategies; ornithinemia; patient advocacy group; prevent; programs; public health relevance; relating to nervous system; research study; response; stable isotope; symposium; therapy development; urea cycle; web site

DESCRIPTION (provided by applicant): Urea cycle disorders (UCD) are a group of 8 rare (overall incidence 1:30,000) but devastating inborn errors of metabolism that carry a high mortality and morbidity from the newborn period through adulthood. UCD include deficiencies in any of the six enzymes and two membrane transporters involved in urea biosynthesis: N-acetylglutamate synthase deficiency (NAGSD); Carbamyl phosphate synthase I deficiency (CPS1D); Ornithine transcarbamylase deficiency (OTCD); Argininosuccinate synthase deficiency (ASSD); Argininosuccinatelyase deficiency (ASLD); Arginase (ARGID) deficiency (Argininemia); Hyperornithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome; and Citrullinemia type II . A decade ago we created the Urea Cycle Disorders Consortium (UCDC) as one of the first members of the Rare Diseases Clinical Research Network (RDCRN) and have subsequently conducted 11 research protocols aimed at understanding the natural history of UCD, developing biomarkers of morbidity and testing novel therapies. Currently the UCDC consists of 14 sites in the U.S., Canada and Europe with an interdisciplinary team of over 60 investigators and staff. The consortium works closely with the National Urea Cycle Disorders Foundation, the patient advocacy organization for UCD and has collaborations with industry to develop innovative therapies for these disorders. We propose in this application 3 full clinical research projects and 3 pilot projects. In the clinical projects we will: 1) Expand our longitudina study that investigates the natural history, morbidity, mortality and biomarkers in children and adults with UCD; 2) Perform a Phase II trial of inorganic nitrites to assess efficacy in correcting nitric oxide deficiency and its consequences in ASLD; and 3) Assess neural and cognitive mechanisms of injury in OTCD, ASLD and ASSD using neuropsychological testing combined with structural MRI, functional MRI, and magnetic resonance spectroscopy. In the proposed pilot projects we will investigate NexGen sequencing for newborn screening of NAGSD, CPS1D and OTCD; perform a trial of urease inhibitors to decrease N accumulation; and use the DMCC maintained contact registry to study compliance with clinical guidelines. In addition to the research studies, we will expand and enhance our website for educational and research resources and continue to provide training and career development opportunities through our educational programs.

描述（由申请人提供）：尿素循环障碍（UCD）是一组8例罕见（总发病率1:30 000）但具有破坏性的先天性代谢错误，从新生儿期到成年期具有高死亡率和发病率。UCD包括参与尿素生物合成的六种酶和两种膜转运蛋白中的任何一种缺乏：n -乙酰谷氨酸合成酶缺乏（NAGSD）；氨甲酰磷酸合成酶I缺乏症（CPS1D）；鸟氨酸转氨基甲酰基酶缺乏症；精氨酸琥珀酸合成酶缺乏症；精氨酸琥珀酸酶缺乏症；精氨酸酶缺乏（Argininemia）；高鸟氨酸血症、高氨血症、高氮尿（HHH）综合征；和瓜氨酸血症II型。十年前，作为罕见病临床研究网络（RDCRN）的首批成员之一，我们创建了尿素循环疾病联盟（UCDC），并随后开展了11项研究方案，旨在了解UCD的自然史，开发发病率的生物标志物和测试新疗法。目前，UCDC在美国，加拿大和欧洲拥有14个站点，拥有一支由60多名研究人员和工作人员组成的跨学科团队。该联盟与国家尿素循环疾病基金会（UCD的患者倡导组织）密切合作，并与工业界合作开发针对这些疾病的创新疗法。我们在此申请中提出3个完整的临床研究项目和3个试点项目。在临床项目中，我们将：1)扩大我们的纵向研究，调查儿童和成人UCD的自然史、发病率、死亡率和生物标志物；2)进行无机亚硝酸盐的II期试验，以评估其矫正效果